$NOVO B (-7,96 %) announced that an oral version of its drug Rybelsus failed to meet the main goal in late-stage trials testing whether it could slow cognitive decline in Alzheimer’s Disease patients.
Will this company ever be able to publish good news? 🥹📉
https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-shares-fall-after-deal-with-trump-slash-obesity-drug-prices-2025-11-07/